ArticlebioRxiv : the preprint server for biology2025
Live-cell analyses with unsegmented images to study cancer cell response to modified T cell therapy.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Live-cell imaging (LCI) of modified T cells co-cultured with cancer cells is commonly used to quantify T cell anti-cancer function. Videos captured by LCI show complex multi-cell behavioral phenotypes that go beyond simple cancer cell fluorescence measurements. Here, we develop an unsupervised analysis workflow to characterize LCI data generated using the Incucyte imaging platform. Unlike most LCI analyses, we avoid cell segmentation due to the low spatiotemporal resolution of the LCI videos and high levels of cell-cell contact. Instead, we develop methods that identify global aggregation patterns and local cellular keypoints to characterize the multicellular interactions that determine cancer cell sensitivity to, or escape from, T cell surveillance. We demonstrate our segmentation-free live-cell behavioral analysis (SF-LCBA) methods on TCR T cells from four donors with varying proportions of cells with a beneficial RASA2 knockout and effector-to-target initial concentrations in a co-culture with A375 melanoma cells. We find that different T cell modifications affect the spatiotemporal dynamics of multicellular aggregate formation. In particular, we show that fewer and smaller cancer cell aggregates form at high ratios of effector T cells to target cancer cells and high titrations of T cells with RASA2 knockouts. Our SF-LCBA method identifies, characterizes, and tracks cellular aggregate formation in datasets that are unsuitable for cell segmentation and tracking, opening the door to more therapeutically-relevant measurements of modified T cell therapy cell behavioral phenotypes from LCI data.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.